Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Potent LpxC Inhibitors with In Vitro Activity Against Multi-Drug Resistant Pseudomonas aeruginosa.

Krause KM, Haglund CM, Hebner C, Serio AW, Lee G, Nieto V, Cohen F, Kane TR, Machajewski TD, Hildebrandt D, Pillar C, Thwaites M, Hall D, Miesel L, Hackel M, Burek A, Andrews LD, Armstrong E, Swem L, Jubb A, Cirz RT.

Antimicrob Agents Chemother. 2019 Aug 26. pii: AAC.00977-19. doi: 10.1128/AAC.00977-19. [Epub ahead of print]

PMID:
31451507
2.

Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.

Noel AR, Attwood M, Bowker KE, Kim A, Krause KM, MacGowan AP.

Int J Antimicrob Agents. 2019 Jul 9. pii: S0924-8579(19)30181-5. doi: 10.1016/j.ijantimicag.2019.07.001. [Epub ahead of print]

PMID:
31299297
3.

Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.

Cohen F, Aggen JB, Andrews LD, Assar Z, Boggs J, Choi T, Dozzo P, Easterday AN, Haglund CM, Hildebrandt DJ, Holt MC, Joly K, Jubb A, Kamal Z, Kane TR, Konradi AW, Krause KM, Linsell MS, Machajewski TD, Miroshnikova O, Moser HE, Nieto V, Phan T, Plato C, Serio AW, Seroogy J, Shakhmin A, Stein AJ, Sun AD, Sviridov S, Wang Z, Wlasichuk K, Yang W, Zhou X, Zhu H, Cirz RT.

ChemMedChem. 2019 Aug 20;14(16):1560-1572. doi: 10.1002/cmdc.201900287. Epub 2019 Aug 5.

PMID:
31283109
4.

Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae.

Serio AW, Keepers T, Krause KM.

Open Forum Infect Dis. 2019 Mar 12;6(4):ofz123. doi: 10.1093/ofid/ofz123. eCollection 2019 Apr.

5.

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL; CARE Study Group.

N Engl J Med. 2019 Feb 21;380(8):791-793. doi: 10.1056/NEJMc1807634. No abstract available.

PMID:
30786196
6.

Once-Daily Plazomicin for Complicated Urinary Tract Infections.

Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP; EPIC Study Group.

N Engl J Med. 2019 Feb 21;380(8):729-740. doi: 10.1056/NEJMoa1801467.

PMID:
30786187
7.

In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.

Castanheira M, Davis AP, Serio AW, Krause KM, Mendes RE.

Diagn Microbiol Infect Dis. 2019 May;94(1):73-77. doi: 10.1016/j.diagmicrobio.2018.10.023. Epub 2018 Dec 5.

PMID:
30661726
8.

Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation.

Serio AW, Keepers T, Andrews L, Krause KM.

EcoSal Plus. 2018 Nov;8(1). doi: 10.1128/ecosalplus.ESP-0002-2018. Review.

PMID:
30447062
9.
10.

Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.

Thwaites M, Hall D, Stoneburner A, Shinabarger D, Serio AW, Krause KM, Marra A, Pillar C.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):338-345. doi: 10.1016/j.diagmicrobio.2018.07.006. Epub 2018 Jul 11.

11.

Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.

Thwaites M, Hall D, Shinabarger D, Serio AW, Krause KM, Marra A, Pillar C.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00236-18. doi: 10.1128/AAC.00236-18. Print 2018 Aug.

12.

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model.

Abdelraouf K, Kim A, Krause KM, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e01074-18. doi: 10.1128/AAC.01074-18. Print 2018 Aug.

13.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes.

Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00313-18. doi: 10.1128/AAC.00313-18. Print 2018 Aug.

14.

The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.

Humphries RM, Kircher S, Ferrell A, Krause KM, Malherbe R, Hsiung A, Burnham CA.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00437-18. doi: 10.1128/JCM.00437-18. Print 2018 Aug. Review.

15.

Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.

Cox G, Ejim L, Stogios PJ, Koteva K, Bordeleau E, Evdokimova E, Sieron AO, Savchenko A, Serio AW, Krause KM, Wright GD.

ACS Infect Dis. 2018 Jun 8;4(6):980-987. doi: 10.1021/acsinfecdis.8b00001. Epub 2018 Apr 19.

16.

Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2.

Sleger T, Gangl E, Pop-Damkov P, Krause KM, Laud PJ, Slee AM, Nichols WW.

J Chemother. 2018 Apr;30(2):95-100. doi: 10.1080/1120009X.2017.1405609. Epub 2017 Nov 30.

17.

Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.

Denervaud-Tendon V, Poirel L, Connolly LE, Krause KM, Nordmann P.

J Antimicrob Chemother. 2017 Oct 1;72(10):2787-2791. doi: 10.1093/jac/dkx239.

PMID:
29091226
18.

Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.

Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I.

Infect Dis Ther. 2017 Jun;6(2):233-243. doi: 10.1007/s40121-017-0150-5. Epub 2017 Mar 11.

19.

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.

Buyck JM, Luyckx C, Muccioli GG, Krause KM, Nichols WW, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2017 May 1;72(5):1400-1409. doi: 10.1093/jac/dkw587.

PMID:
28137941
20.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
21.

Aminoglycosides: An Overview.

Krause KM, Serio AW, Kane TR, Connolly LE.

Cold Spring Harb Perspect Med. 2016 Jun 1;6(6). pii: a027029. doi: 10.1101/cshperspect.a027029. Review.

22.

The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.

Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW.

Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.

23.

Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.

Asli A, Brouillette E, Krause KM, Nichols WW, Malouin F.

Antimicrob Agents Chemother. 2015 Nov 16;60(2):752-6. doi: 10.1128/AAC.02102-15. Print 2016 Feb.

24.

In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.

Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R.

Antimicrob Agents Chemother. 2015 Dec;59(12):7842-6. doi: 10.1128/AAC.02019-15. Epub 2015 Sep 21.

25.

Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.

Jones RN, Holliday NM, Krause KM.

Antimicrob Agents Chemother. 2015 Aug;59(8):5036-9. doi: 10.1128/AAC.00021-15. Epub 2015 May 26.

26.

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations.

Keepers TR, Gomez M, Biek D, Critchley I, Krause KM.

Int Sch Res Notices. 2015 May 19;2015:489547. doi: 10.1155/2015/489547. eCollection 2015.

27.

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.

Dallow J, Otterson LG, Huband MD, Krause KM, Nichols WW.

Int J Antimicrob Agents. 2014 Dec;44(6):552-6. doi: 10.1016/j.ijantimicag.2014.07.023. Epub 2014 Sep 16.

PMID:
25293578
28.

Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Keepers TR, Gomez M, Celeri C, Nichols WW, Krause KM.

Antimicrob Agents Chemother. 2014 Sep;58(9):5297-305. doi: 10.1128/AAC.02894-14. Epub 2014 Jun 23.

29.

Beef heifer growth and reproductive performance following two levels of pasture allowance during the fall grazing period.

Bailey BL, Griggs TC, Rayburn EB, Krause KM.

J Anim Sci. 2014 Aug;92(8):3659-69. doi: 10.2527/jas.2013-7121. Epub 2014 Jun 19.

PMID:
24948653
30.

Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.

Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS.

Antimicrob Agents Chemother. 2014;58(2):833-8. doi: 10.1128/AAC.01896-13. Epub 2013 Nov 18.

31.

Ultrathin-layer chromatography nanostructures modified by atomic layer deposition.

Jim SR, Foroughi-Abari A, Krause KM, Li P, Kupsta M, Taschuk MT, Cadien KC, Brett MJ.

J Chromatogr A. 2013 Jul 19;1299:118-25. doi: 10.1016/j.chroma.2013.05.050. Epub 2013 May 25.

PMID:
23768654
32.

Do high-risk preschoolers or overweight mothers meet AAP-recommended behavioral goals for reducing obesity?

Turer CB, Stroo M, Brouwer RJ, Krause KM, Lovelady CA, Bastian LA, Peterson B, Østbye T.

Acad Pediatr. 2013 May-Jun;13(3):243-50. doi: 10.1016/j.acap.2013.01.003. Epub 2013 Jan 9.

33.

Diet quality and weight change among overweight and obese postpartum women enrolled in a behavioral intervention program.

Wiltheiss GA, Lovelady CA, West DG, Brouwer RJ, Krause KM, Østbye T.

J Acad Nutr Diet. 2013 Jan;113(1):54-62. doi: 10.1016/j.jand.2012.08.012. Epub 2012 Nov 10.

34.

In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia.

Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):429-31. doi: 10.1016/j.diagmicrobio.2012.08.010. Epub 2012 Oct 16.

PMID:
23083812
35.

Parent-focused change to prevent obesity in preschoolers: results from the KAN-DO study.

Østbye T, Krause KM, Stroo M, Lovelady CA, Evenson KR, Peterson BL, Bastian LA, Swamy GK, West DG, Brouwer RJ, Zucker NL.

Prev Med. 2012 Sep;55(3):188-95. doi: 10.1016/j.ypmed.2012.06.005. Epub 2012 Jun 13.

36.

Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.

Blais J, Lewis SR, Krause KM, Benton BM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1584-7. doi: 10.1128/AAC.05532-11. Epub 2011 Dec 27.

37.

Predictors of postpartum weight change among overweight and obese women: results from the Active Mothers Postpartum study.

Østbye T, Peterson BL, Krause KM, Swamy GK, Lovelady CA.

J Womens Health (Larchmt). 2012 Feb;21(2):215-22. doi: 10.1089/jwh.2011.2947. Epub 2011 Nov 17.

38.

Postpartum physical activity in overweight and obese women.

Durham HA, Morey MC, Lovelady CA, Namenek Brouwer RJ, Krause KM, Østbye T.

J Phys Act Health. 2011 Sep;8(7):988-93.

39.

Effects of essential oils on rumen fermentation, milk production, and feeding behavior in lactating dairy cows.

Tager LR, Krause KM.

J Dairy Sci. 2011 May;94(5):2455-64. doi: 10.3168/jds.2010-3505.

40.

In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.

Farrell DJ, Krause KM, Benton BM.

Diagn Microbiol Infect Dis. 2011 Mar;69(3):275-9. doi: 10.1016/j.diagmicrobio.2010.09.017.

PMID:
21353951
41.

Kids and adults now! Defeat Obesity (KAN-DO): rationale, design and baseline characteristics.

Ostbye T, Zucker NL, Krause KM, Lovelady CA, Evenson KR, Peterson BL, Bastian LA, Swamy GK, West DG, Brouwer RJ.

Contemp Clin Trials. 2011 May;32(3):461-9. doi: 10.1016/j.cct.2011.01.017. Epub 2011 Feb 18.

42.

Indium tin oxide nanopillar electrodes in polymer/fullerene solar cells.

Rider DA, Tucker RT, Worfolk BJ, Krause KM, Lalany A, Brett MJ, Buriak JM, Harris KD.

Nanotechnology. 2011 Feb 25;22(8):085706. doi: 10.1088/0957-4484/22/8/085706. Epub 2011 Jan 18.

PMID:
21242635
43.

Comparison of dietary intake of overweight postpartum mothers practicing breastfeeding or formula feeding.

Durham HA, Lovelady CA, Brouwer RJ, Krause KM, Ostbye T.

J Am Diet Assoc. 2011 Jan;111(1):67-74. doi: 10.1016/j.jada.2010.10.001.

44.

Taking a little off the top: nanorod array morphology and growth studied by focused ion beam tomography.

Krause KM, Vick DW, Malac M, Brett MJ.

Langmuir. 2010 Nov 16;26(22):17558-67. doi: 10.1021/la103070x. Epub 2010 Sep 29.

PMID:
20879751
45.

In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.

Krause KM, Barriere SL, Kitt MM, Benton BM.

Diagn Microbiol Infect Dis. 2010 Oct;68(2):181-5. doi: 10.1016/j.diagmicrobio.2010.05.008.

PMID:
20846593
46.

Predictors of breastfeeding in overweight and obese women: data from Active Mothers Postpartum (AMP).

Krause KM, Lovelady CA, Østbye T.

Matern Child Health J. 2011 Apr;15(3):367-75. doi: 10.1007/s10995-010-0667-7.

47.

Gestational weight gain in consecutive pregnancies.

Chin JR, Krause KM, Ostbye T, Chowdhury N, Lovelady CA, Swamy GK.

Am J Obstet Gynecol. 2010 Sep;203(3):279.e1-6. doi: 10.1016/j.ajog.2010.06.038.

PMID:
20816151
48.

Effect of breastfeeding on weight retention from one pregnancy to the next: results from the North Carolina WIC program.

Østbye T, Krause KM, Swamy GK, Lovelady CA.

Prev Med. 2010 Nov;51(5):368-72. doi: 10.1016/j.ypmed.2010.07.017. Epub 2010 Jul 23.

PMID:
20655944
49.

Effect of breast-feeding on weight retention at 3 and 6 months postpartum: data from the North Carolina WIC Programme.

Krause KM, Lovelady CA, Peterson BL, Chowdhury N, Østbye T.

Public Health Nutr. 2010 Dec;13(12):2019-26. doi: 10.1017/S1368980010001503. Epub 2010 Jun 2.

PMID:
20519049
50.

Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.

Hill CM, Krause KM, Lewis SR, Blais J, Benton BM, Mammen M, Humphrey PP, Kinana A, Janc JW.

Antimicrob Agents Chemother. 2010 Jul;54(7):2814-8. doi: 10.1128/AAC.01737-09. Epub 2010 Apr 19.

Supplemental Content

Loading ...
Support Center